|
|
Volumn 277, Issue 4, 2002, Pages 2644-2649
|
|
Heparin inhibits the binding of β2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome
a
b
b
a
c
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODIES;
BLOOD;
MUTAGENESIS;
PATIENT TREATMENT;
PHOSPHOLIPIDS;
ANTICOAGULATION THERAPY;
PROTEINS;
AUTOANTIBODY;
BETA2 GLYCOPROTEIN 1;
HEPARIN;
LYSINE;
PHOSPHOLIPID;
PLASMIN;
ANTICOAGULATION;
ANTIGEN RECOGNITION;
ANTIPHOSPHOLIPID SYNDROME;
ARTICLE;
BINDING SITE;
CONTROLLED STUDY;
HUMAN;
PRIORITY JOURNAL;
PROTEIN BINDING;
PROTEIN BLOOD LEVEL;
PROTEIN INTERACTION;
SITE DIRECTED MUTAGENESIS;
ANTICOAGULANTS;
ANTIPHOSPHOLIPID SYNDROME;
BETA 2-GLYCOPROTEIN I;
BINDING SITES;
BINDING, COMPETITIVE;
CARDIOLIPINS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ELECTROPHORESIS, POLYACRYLAMIDE GEL;
GLYCOPROTEINS;
HAPTOGLOBINS;
HEPARIN;
HUMANS;
LYSINE;
MODELS, BIOLOGICAL;
MUTAGENESIS, SITE-DIRECTED;
MUTATION;
PEPTIDES;
PHOSPHOLIPIDS;
PLASMIN;
PROTEIN BINDING;
PROTEIN STRUCTURE, TERTIARY;
TIME FACTORS;
|
|
EID: 0037169563
PISSN: 00219258
EISSN: None
Source Type: Journal
DOI: 10.1074/jbc.M110176200 Document Type: Article |
|
Times cited : (73)
|
|
References (39)
|
